We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ipso Ventures | LSE:IPS | London | Ordinary Share | GB00B1GDWB47 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.425 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
09/11/2011 10:09 | Hi everyone, I just bought 56,377 shares @ 3.59p, but showing as a SELL on PLUS market, just so everyone holding here is aware. | moochy | |
09/11/2011 08:55 | Yes Tomboy... it has been a while since any news from the company. I see the share price is sliding back to the lowly reaches of 3p..... All this time cash is burning... burning... burning... what will come first, another fund raising exercise or another early sale of one of their technologies... very poor... must try harder.... Then again the management dont exactly have a good pedigree do they... I suppose their other businesses failing does allow them more time to muck this one up. | electrick | |
09/11/2011 08:39 | October 2011 Buccolam granted first PUMA Buccolam® (Midazolam, Oromucosal Solution) Granted European Marketing Authorization for Treatment of Acute Seizures - Approval offers convenient alternative to treat seizures in children and adolescents - First ever product approved through European Commission's Centralized Paediatric Use Marketing Authorization (PUMA) Therakind is delighted to announce that the European Commission has granted (September 2011) a Centralized Paediatric Use Marketing Authorization (PUMA) for Buccolam® (midazolam, oromucosal solution), for treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents, from 3 months to less than 18 years of age. Buccolam is being marketed by Viropharma (www.viropharma.com) Therakind was responsible for the regulatory development strategy for the product as well as the design, management and sponsoring of the clinical trial. This is the first product approval through the centralized PUMA procedure since its inception. Buccal midazolam is already being used routinely in the treatment of acute seizures in children both in the UK and Europe but in an unlicensed form. It is now approved throughout all the Member States of the European Union (EU) as well as in the European Economic Area (EEA), namely Norway, Iceland and Liechtenstein. Buccolam is oromucosal midazolam provided in a pre-filled, age-specific dose formulation for convenient buccal (i.e. via the cavity between the cheek and gum) delivery. Buccal midazolam has been shown in four clinical studies to be either comparable or superior in both its effectiveness and speed of onset of action to the current standard treatment, rectally-administere Therakind sold its controlling interest in Buccolam® in 2010. The Company received a milestone payment on the granting of marketing approval for the product, and will receive royalties on product sales. For further information, please contact us. | tomboyb | |
03/11/2011 18:15 | Viropharm results - a mention of Buccolam - What management need to address is what royalties are the expecting ( what milestone payment was recieved) - And how is the progress of their pain drug going - Cambridge Meditech - Formflex range of products with Lantor - Licensing agreement due? Ipsol Energy - Stake worth £457k - Medermica - Any news on that - is one of the largest investments? PH sensor / etc Polyfect - Cheaper plastic technology - | tomboyb | |
03/11/2011 14:00 | thems the traders... watch the spread and how quick it falls back to 3 p this time... shocking ... | electrick | |
03/11/2011 11:17 | And profit i took, 50k in and out for 0.55p profit per share. | kinghorm23 | |
03/11/2011 09:05 | All buys today, plus buyers 35k paying 3.59p | kinghorm23 | |
03/11/2011 08:25 | Maybe i should adopt some topinfo/moreforus ramping here now i have just bought 50k ? "not selling until 20p" "this will hit 10p today" Will that do, in a nutshell if it has a run i will take a profit simples. | kinghorm23 | |
03/11/2011 07:53 | perhaps touch under 3 p today...... traders keep some interest / momentum but it is fading... just like the SP | electrick | |
02/11/2011 21:50 | All the pump and dumpers long gone from here ! moreforus/topinfo/fa Nowhere to be seen. Guess it's time to buy when quiet and this lot are not in pump and dumping it. | kinghorm23 | |
26/10/2011 14:56 | well it made the intra day of 2.7p... perhaps this time it will continue the slide... or perhap a painful optimism as it continued to haemorrhage cash whilst receiving nothing back in the door.... COST still higher than Income... delays in its technologies major stakerholder left and sold up company directors with a track record of failed companies cash calls to prop it up but i love the optimism here... its why I stick about | electrick | |
26/10/2011 14:36 | i like your thinking Huckle..... | electrick | |
26/10/2011 14:05 | perhaps 3p later today? whaddya think? | electrick | |
24/10/2011 14:24 | life again in the sp | fur | |
24/10/2011 08:43 | shouldnt affect directly unless you consider the directors abilities to manage companies in this difficult market pertinent | electrick |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions